title: Short hairpin RNA targeting 2B gene of coxsackievirus B3 exhibits potential antiviral effects both in vitro and in vivo.
abstract: BACKGROUND
  Coxsackievirus B3 is an important infectious agent of viral myocarditis, pancreatitis and aseptic meningitis, but there are no specific antiviral therapeutic reagents in clinical use. RNA interference-based technology has been developed to prevent the viral infection.
  
  
  METHODS
  To evaluate the impact of RNA interference on viral replication, cytopathogenicity and animal survival, short hairpin RNAs targeting the viral 2B region (shRNA-2B) expressed by a recombinant vector (pGCL-2B) or a recombinant lentivirus (Lenti-2B) were tansfected in HeLa cells or transduced in mice infected with CVB3.
  
  
  RESULTS
  ShRNA-2B exhibited a significant effect on inhibition of viral production in HeLa cells. Furthermore, shRNA-2B improved mouse survival rate, reduced the viral tissues titers and attenuated tissue damage compared with those of the shRNA-NC treated control group. Lenti-2B displayed more effective role in inhibition of viral replication than pGCL-2B in vivo.
  
  
  CONCLUSIONS
  Coxsackievirus B3 2B is an effective target of gene silencing against coxsackievirus B3 infection, suggesting that shRNA-2B is a potential agent for further development into a treatment for enterviral diseases.
authors.affiliation: Molecular Immunology Laboratory, Capital Institute of Pediatrics, YaBao Road 2, Beijing, 100020, China.
authors.forename: Hailan
authors.initials: H
authors.lastname: Yao
authors.forename: Yangde
authors.initials: Y
authors.lastname: Zhang
authors.forename: Feng
authors.initials: F
authors.lastname: He
authors.forename: Caihong
authors.initials: C
authors.lastname: Wang
authors.forename: Zonghui
authors.initials: Z
authors.lastname: Xiao
authors.forename: Jizhen
authors.initials: J
authors.lastname: Zou
authors.forename: Fang
authors.initials: F
authors.lastname: Wang
authors.forename: Zhewei
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001688:Biological Products / Q000008:administration & dosage* / Q000494:pharmacology; D003384:Coxsackievirus Infections / Q000188:drug therapy* / Q000821:virology; D004195:Disease Models, Animal; D029822:Enterovirus B, Human / Q000187:drug effects* / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology; D016019:Survival Analysis; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D001688:Biological Products; D034741:RNA, Small Interfering